期刊
MOUNT SINAI JOURNAL OF MEDICINE
卷 75, 期 3, 页码 204-225出版社
WILEY
DOI: 10.1002/msj.20043
关键词
alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid; antidepressant; corticotropin-releasing factor; cytokines; glutamate; hypothalamic-pituitary-adrenal; neurotrophic factors; N-methyl-D-aspartate; plasticity; melatonin; substance P
资金
- NIMH NIH HHS [K02 MH076222-01A1] Funding Source: Medline
The first effective antidepressants, monoamine oxidase inhibitors and tricyclic antidepressants; were identified 50 years ago, largely through serendipity. These medications were found to improve mood in a little more than half of depressed patients after a few weeks of chronic use. Almost all antidepressants prescribed today were developed through minor modifications of these original antidepressants and. like monoamine oxidase inhibitors and tricyclic antidepressants, act primarily through monoaminergic mechanisms. Although there have been improvements in side-effect profiles and over-dose toxicity, these never medications have not provided substantial advances in the efficacy and speed of the antidepressant effect for patients. Over the last 2 decades, our understanding of the neurobiology underlying depression h,,is expanded exponentially. Given this expansion; we may he nearing an inflection point in antidepressant drug development. at which useful medicines will be designed through a rational understanding of the biological systems. In this review, we discuss the biological basis and preclinical and clinical evidence for a series of promising classes of antidepressants developed primarily out of a pathophysiologically informed approach.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据